Breast Cancer | Specialty

SAR439859 Achieves On-Target Activity in Metastatic ER+ Breast Cancer

December 28th 2020

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.

Fixed-Dose Pertuzumab/Trastuzumab Combo Approved in Europe for HER2+ Breast Cancer

December 23rd 2020

December 23, 2020 - The European Commission has approved the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, to be administered via a subcutaneous injection in the treatment of patients with early and metastatic HER2-positive breast cancer.

Rapid Readouts: Updated Results From KX-ORAX-001 Study

December 23rd 2020

Rapid Readouts: Updated Results From DESTINY-Breast01

December 23rd 2020

Dr. Pusztai on the Promise of ctDNA Assays in Breast Cancer

December 22nd 2020

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

December 22nd 2020

December 22, 2020 — Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor–positive, estrogen receptor–positive metastatic breast cancer.

ELAINE-2 Trial Could Establish the Actionability of ESR1 in HR+/HER2- Breast Cancer

December 21st 2020

Matthew P. Goetz, MD, discusses ongoing research in the setting of ESR1-mutant, ER–positive, HER2-negative metastatic breast cancer.

Dr. Rao on Emerging Treatments in HER2+ Metastatic Breast Cancer

December 17th 2020

Ruta D. Rao, MD, associate professor in the Department of Medicine, Division of Hematology at Rush Medical College, as well as the director of the Coleman Foundation Comprehensive Breast Cancer Clinic and medical director of Rush University Cancer Center, discusses emerging treatments for patients with HER2-positive metastatic breast cancer.

Dr. Jhaveri on Sequencing Treatments in Metastatic HER2+ Breast Cancer

December 17th 2020

Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses sequencing treatments for patients with metastatic HER2-positive breast cancer.

Overcoming CDK4/6 Inhibitor Resistance in ESR1-Mutant HR+/HER2- Breast Cancer

December 17th 2020

Massimo Cristofanilli, MD, highlights the introduction of CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib, which has been a significant addition to the hormone receptor–positive, HER2-negative breast cancer armamentarium.

Dr. Sammons on Research Efforts Examining Lasofoxifene in ESR1-Mutant Breast Cancer

December 17th 2020

Sarah Sammons, MD, discusses clinical trials examining lasofoxifene in patients with ESR1-mutant breast cancer.

FDA Approves Margetuximab-cmkb Plus Chemo in Pretreated Metastatic HER2+ Breast Cancer

December 16th 2020

December 16, 2020 - The FDA has approved margetuximab-cmkb plus chemotherapy for use in adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which was for metastatic disease.

Giant of Cancer Care® Eric Winer Elected ASCO President for 2022-2023 Term

December 16th 2020

December 16, 2020 - Eric P. Winer, MD, FASCO, 2019 OncLive Giants of Cancer Care® recipient in Breast Cancer, has been elected to serve as the president of ASCO for the 2022-2023 term, and will assume the president-elect position during the 2020 ASCO Annual Meeting.

Trastuzumab Deruxtecan Approaches EU Approval for HER2+ Metastatic Breast Cancer

December 15th 2020

December 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2–based regimens.

TNBC Treatment Paradigm Advances With the Rise of Chemoimmunotherapy Combos

December 15th 2020

Neelima Vidula, MD, highlights some of the pivotal trials evaluating immunotherapy combination regimens in triple-negative breast cancer, some of the challenges faced in practice, and areas for further exploration.

Dr. Pusztai on the Role of ctDNA as a Biomarker in Breast Cancer

December 15th 2020

Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.

Neratinib Improves PFS in HER2+ Breast Cancer With Brain Metastases

December 14th 2020

December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.

Dr. Hamilton on the Mechanism of Action of OP-1250 in HR+/HER2- Metastatic Breast Cancer

December 12th 2020

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Harbeck on Ki-67 as a Biomarker for Identifying High-Risk Early Breast Cancer

December 12th 2020

Nadia Harbeck, MD, PhD, discusses Ki-67 as a biomarker for identifying patients with high-risk early breast cancer who received treatment on the monarchE trial.

Tucatinib Triplet Prolongs Time to Deterioration of HRQOL in HER2+ Breast Cancer With Brain Metastases

December 12th 2020

December 11, 2020 - Tucatinib in combination with trastuzumab and capecitabine significantly prolonged the time to deterioration of health-related quality of life in patients with HER2- positive metastatic breast cancer with brain metastases.